Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus
Main Authors: | Warner Robinson, DDS, Beth N. McLellan, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | JAAD Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352512623003533 |
Similar Items
-
Vitiligo during dupilumab therapy
by: Vincenzo Picone, MD, et al.
Published: (2023-06-01) -
Corneal Refractive Surgery Considerations in Patients on Dupilumab
by: Majid Moshirfar, et al.
Published: (2022-06-01) -
A review of dupilumab in the treatment of atopic diseases
by: Quinn Thibodeaux, et al.
Published: (2019-09-01) -
A case of dupilumab used to treat the exaggerated response to insect bites in the setting of chronic lymphocytic leukemia
by: William Guo, MD, et al.
Published: (2024-03-01) -
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma
by: Caroline C. Cotton, et al.
Published: (2024-01-01)